Actively Recruiting
PK/PD of Caspofungin in Children Severe Infection
Led by Children's Hospital of Fudan University · Updated on 2026-02-17
60
Participants Needed
2
Research Sites
217 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Caspofungin is an anti-fungal drug mainly metabolized by the liver. The pathophysiological status of children with severe infection will affect the metabolism of caspofungin in the body especially in the case of liver dysfunction. There is little metabolism of caspofungin through the kidney and continuous renal replacement therapy and renal function have little influence on the pharmacokinetics of caspofungin. The study aim to investigate PK/PD of caspofungin in children with specific pathophysiological conditions, such as liver insufficiency, hypoproteinemia, ECMO treatment, or sepsis.
CONDITIONS
Official Title
PK/PD of Caspofungin in Children Severe Infection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children receiving caspofungin in pediatric intensive care unit
You will not qualify if you...
- No informed consent signed
- Participation in other clinical trials
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China, 201102
Actively Recruiting
2
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China, 201102
Actively Recruiting
Research Team
Y
Yixue Wang, doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here